PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerviewpress.com
Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL
Go online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emergence of newer non-covalent BTK options. Throughout, our experts share sound, evidence-based treatment plans designed to address the medical needs of patients progressing on or unable to tolerate BTK covalent inhibitor therapy in the CLL/SLL and MCL settings. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence on the mechanistic properties, safety, and efficacy of covalent and non-covalent BTK inhibitors with therapeutic applications in B-cell malignancies, including in settings where therapeutic intolerance or resistance mutations are present, Develop management models for capturing therapeutic intolerance or BTK resistance mutations at disease progression in patients receiving treatment with covalent BTK inhibitors, Recommend evidence-based management plans addressing the therapeutic and safety needs of patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations or who are unable to continue on therapy due to adverse events.